Toni Choueiri, MD, from the Dana Faber Cancer Institute, Boston, MA, discusses three exciting trials in renal cell carcinoma (RCC) presented at the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain. There was an update on the CABOSUN trial (NCT01835158) which compared caboxantinib and sunitinib. This study has been reviewed recently by an independent reviewer, with cabozantinib still found to be superior to sunitinib, with an even better hazard ratio. The KEYNOTE-564 trial (NCT03142334) is currently recruiting patients to investigate the efficacy of pembrolizumab versus placebo as adjuvant treatment in patients with high risk RCC that have had a nephrectomy. This will hopefully show some promising results. The third trial was investigated the efficacy of savolitinib in papillary non-clear cell RCC patients with MET mutations (NCT030911920). The primary endpoint of this study will be progression free survival, and will hopefully provide an alternative to the current standard of care for these patients.